Key Takeaways GKOS posted 25% YoY revenue growth in Q1 2025 to $106.7M, led by $21M in iDose TR sales. GKOS is advancing a rich pipeline, including Epioxa and PRESERFLO, to fuel long-term growth. GKOS expects mid-single-digit 2025 declines in non-iDose revenues due to LCD and legacy MIGS pressure.Glaukos Corporation (GKOS) continues to reshape the ophthalmology landscape, backed by a record-breaking first-quarter 2025 performance. The company posted revenues of $106.7 million, reflecting a 25% year-over-y ...

Financial Performance & Guidance - Cerus is raising its full-year 2024 product revenue guidance to $177 - $179 million, anticipating a 12-14% increase compared to full-year 2023 product revenue[13] - The bottom end of the 2024 IFC guidance range has been raised to $9 - $10 million, from the prior $8 - $10 million[13] - In Q3 2024, Non-GAAP Adjusted EBITDA reached $4.4 million[32] Product & Market - The global addressable market for INTERCEPT products is estimated at $1.3 billion, with potential growth to over $1.5 billion in 5-7 years[22] - The U S addressable market is $150 million, with potential growth to over $200 million in 5-7 years[22] - Cerus' preliminary 2023 product revenue was $156 million[22] Strategic Initiatives - Cerus has a new BARDA contract for INTERCEPT RBCs[11] - The company submitted a CE Mark for its LED Illuminator[11] - Cerus is focused on adjusted EBITDA and operating cash flow goals[25]

WARSAW, Ind., July 9, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its second quarter earnings conference call will be webcast on Thursday, August 7, 2025 at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET.The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call.Individuals in the ...

CARLSBAD, CALIFORNIA, July 09, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in innovative spine and interventional pain management solutions, today announced initial surgeries using Aurora Spine’s newest product, the AERO™ Lumbar Fusion System, have commenced. The minimally invasive procedures using the AERO were conducted by two different surgeons, one ortho surgeon and one interventionalist. The initial surgeries performed were pr ...

CANADA - 2025/04/03: In this photo illustration, the Abbott Laboratories logo is seen displayed on a ... More smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty Images Abbott Laboratories (NYSE:ABT) has greatly exceeded the broader S&P 500 index this year, with its stock price increasing by 18% compared to the S&P 500’s 6% rise. This strong performance is due to the company’s solid quarterly results and positive future forecasts ...

导读： 西门子发言人在一份声明中表示："我们在中国的强大存在是我们多年来建立的全球制造足迹的一部分，目的是战略性地服务当地市场，并确保将干扰降到 最低。" 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 当地时间7月7日，西门子医疗发言人表示，该公司预计目前在中国的事态发展不会对其业务产生实质性影响。 该发言人在一份声明中表示： "我们在中国的强大存在是我们多年来建立的全球制造足迹的一部分，目的是战略性地服务当地市场，并确保将 干扰降到最低。" 这一立场从侧面彰显了西门子医疗对中国市场的战略坚守。事实上，"中国本地化" 早已是西门子医疗全球战略的核心支柱之一。 依托苏州的影像设备生产基地、西安的 IVD 制造中心等本土布局，西门子医疗在过去十余年间逐步搭建起 "立足中国、服务中国" 的完整能力 体系。 值得注意的是，当前的限制措施并未将在华欧资企业纳入排除范围，这意味着西门子医疗在华注册运营的本地法人公司，依然保有参与政府采 购的资格。 此前，财政部发文称，根据有关法律法规，经批准，财政部决定在政府采购活动中对部分自欧盟进口的医疗器械采取相 ...

在当今快节奏的生活中，睡眠问题逐渐成为困扰许多人的健康隐患。其中，阻塞性睡眠呼吸暂停（Obstructive Sleep Apnea，OSA）作为一种常见的睡眠呼吸 障碍，正悄然影响着无数人的健康。而如今，全球首款支持睡眠呼吸暂停监测的智能戒指——RingConn智能戒指的出现，为这一问题带来了突破性的解决 方案。 睡眠呼吸暂停：高患病率与低诊断率的矛盾现状 阻塞性睡眠呼吸暂停（OSA）是指睡眠过程中上气道反复塌陷阻塞，导致气流受限或完全阻断的睡眠呼吸障碍疾病，主要症状有打鼾、白天嗜睡、注意力不 集中等。它可能损害心血管和代谢系统，是高血压、冠心病、中风等多种高风险慢性疾病的独立危险因素。阻塞性睡眠呼吸暂停低通气综合征（OSAHS） 作为常见且严重的同类疾病，也会影响患者睡眠质量。据了解，25%的打鼾者伴有OSAHS，10%的OSAHS患者可能发展为高血压、中风、认知功能障碍等 疾病。 研究数据显示，OSA的患病率在总体人群中约占3%-7%，成人中占6%-17%，男性比例明显高于女性。全球30-69岁人群中，以睡眠呼吸暂停低通气指数≥5 次/小时为诊断标准，有约9.36亿人患有OSA，其中中重度患者约4.25 ...

ALISO VIEJO, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary financial results for the second quarter 2025 and revised full-year 2025 guidance. The Company will host a conference call on Tuesday, July 8, 2025, at 5:00 p.m. Eastern Time. Preliminary Second Quarter 2025 Results Preliminary second quarter 2025 revenue is ...

BURLINGTON, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the ...

Key Takeaways ISRG placed 367 da Vinci systems in Q1 2025, bringing its global installed base past 10,000 units. ISRG's procedure volume rose 17% YoY, but system utilization grew just 2% across core platforms. ISRG's SP and Ion utilization rose faster; da Vinci 5 show early clinical impact but face rollout hurdles.Intuitive Surgical (ISRG) continues to expand its global dominance in robotic-assisted surgery with a 15% year-over-year increase in da Vinci system installations, bringing its global installed ...